Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVN-944 for administration · 1 trial · 6 indications
| Name | Type | Description |
|---|---|---|
| AVN-944 capsules for oral administration | DRUG | - |
Inclusion Criteria: 1. Histologically or cytologically confirmed chronic myelogenous leukemia, acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, non-Hodgkin's lymphoma or Hodgkin's disease. 2. Patients must be refractory to, intolerant of, or dec...
AVN-944 is an investigational small molecule being studied for the treatment of acute leukemia. It was evaluated in a Phase 1 clinical trial for advanced hematologic malignancies, including acute leukemia, chronic leukemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Waldenstrom's macroglobulinemia.
AVN-944 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The drug is an investigational small molecule in the oncology therapeutic area.
AVN-944 is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing. The drug remains investigational and has not been approved by regulatory authorities.
AVN-944 has been studied in one completed clinical trial, NCT00273936, titled 'Trial of AVN-944 in Patients With Advanced Hematologic Malignancies.' This Phase 1 trial enrolled 72 participants in the United States and was an uncontrolled, non-randomized study.
AVN-944 is also known as AVN-944 for administration. No other alternative names have been disclosed for this investigational drug. It is a small molecule being developed by Vertex Pharmaceuticals for the treatment of hematologic malignancies.